1. Search Result
Search Result
Results for "

ikk-

" in MedChemExpress (MCE) Product Catalog:

117

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

10

Peptides

23

Natural
Products

5

Recombinant Proteins

4

Isotope-Labeled Compounds

16

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13687A
    IKK 16 hydrochloride
    20+ Cited Publications

    IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .
    IKK 16 hydrochloride
  • HY-13687
    IKK 16
    20+ Cited Publications

    IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .
    IKK 16
  • HY-112456

    IKK Inflammation/Immunology
    IKK2-IN-4 (compound 4) is a potent IKK-2 inhibitor, with an IC50 of 25 nM. IKK2-IN-4 can inhibit the LPS-induced production of TNFα in PBMCs .
    IKK2-IN-4
  • HY-111135

    IKK Inflammation/Immunology Cancer
    IKK2-IN-3 (Compound 8) is a potent IKK2 inhibitor with an IC50 of 0.075 μM .
    IKK2-IN-3
  • HY-13873
    IKK-IN-1
    1 Publications Verification

    IKK Inflammation/Immunology
    IKK-IN-1 is an inhibitor of IKK extracted from patent WO2002024679A1, compound example 18-13.
    IKK-IN-1
  • HY-13060
    ACHP Hydrochloride
    5+ Cited Publications

    ikk-2 Inhibitor VIII

    IKK Inflammation/Immunology
    ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective IKK-β inhibitor with an IC50 of 8.5 nM.
    ACHP Hydrochloride
  • HY-10172
    IMD-0354
    15+ Cited Publications

    ikk2 Inhibitor V

    IKK Cancer
    IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity . IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM .
    IMD-0354
  • HY-13687R

    IKK LRRK2 Reference Standards P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related Inflammation/Immunology
    IKK 16 (Standard) is the analytical standard of IKK 16. This product is intended for research and analytical applications. IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
    IKK 16 (Standard)
  • HY-136392

    IKK Inflammation/Immunology
    IKK-IN-3 is a potent and selective IkappaB kinase 2 (IKK2 or IKKβ) inhibitor, with IC50s of 19 and 400 nM for IKK2 and IKK1 (or IKKα), respectively .
    IKK-IN-3
  • HY-136393

    IKK Inflammation/Immunology
    IKK-IN-4 is a potent and selective IkappaB kinase 2 (IKKβ orIKK2) inhibitor, with IC50s of 45 and 650 nM for IKKβ and IKKα, respectively .
    IKK-IN-4
  • HY-10172R

    ikk2 Inhibitor V (Standard)

    Reference Standards IKK Cancer
    IMD-0354 (Standard) is the analytical standard of IMD-0354. This product is intended for research and analytical applications. IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity . IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM .
    IMD-0354 (Standard)
  • HY-E70831

    IKK Cancer
    IκB kinase α (IKKα), one of the two catalytic subunits of the IKK complex involved in NF-κB activation, also functions as a molecular switch that controls epidermal differentiation. IKKα Recombinant Human Active Protein Kinase is a recombinant IKKα protein that can be used to study IKKα-related functions .
    IKKα Recombinant Human Active Protein Kinase
  • HY-P1847

    NF-κB Cancer
    IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .
    IKKγ NBD Inhibitory Peptide
  • HY-P1847A

    NF-κB Inflammation/Immunology
    IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .
    IKKγ NBD Inhibitory Peptide TFA
  • HY-163412

    IKK Inflammation/Immunology
    IKKβ-IN-3 (Compound hit4) is a IKKβ inhibitor with an IC50 value of 30.4 nM. IKKβ is a key enzyme in the NF-κB signaling pathway and is involved in the development of many diseases. IKKβ-IN-3 can be used in the study of CAF-induced arthritis .
    IKKβ-IN-3
  • HY-W028127

    IKK Inflammation/Immunology
    IKKβ-IN-4 (compound 14) is an IkappaB kinase-β ( IKKβ ) inhibitor with IC50 value of 1.9 μM. IKKβ is a key enzyme in the NF-κB signaling pathway and is involved in the development of many diseases .
    IKKβ-IN-4
  • HY-146723

    IKK Inflammation/Immunology
    IKKβ-IN-1 is a potent and orally active IkappaB (IKK-β) inhibitor with IC50 of 0.20 μM. IKKβ-IN-1 can reduce PGE2 and TNF-α production in mouse macrophage cells. IKKβ-IN-1 has the ability to protect mice against septic shock induced mortality .
    IKKβ-IN-1
  • HY-10519
    BMS-345541
    25+ Cited Publications

    IKK Cancer
    BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
    BMS-345541
  • HY-10518
    BMS-345541 hydrochloride
    25+ Cited Publications

    IKK Cancer
    BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
    BMS-345541 hydrochloride
  • HY-12453
    TBK1/IKKε-IN-2
    2 Publications Verification

    IKK Inflammation/Immunology
    TBK1/IKKε-IN-2 is a dual TBK1 and IKKε inhibitor.
    TBK1/IKKε-IN-2
  • HY-138931

    IKK Cancer
    TBK1/IKKε-IN-6 (example 110) is a TBK1 and IKKε inhibitor, with IC50 values of <100 nM for both TBK1 and IKKε .
    TBK1/IKKε-IN-6
  • HY-69047

    IKK Cancer
    6-Chloro-7-deazaguanine (compound 63) is an inactive molecule of IKK (lacking the critical 5-cyano group), targeting IKKα and IKKβ with Ki values both greater than 30 μM. IKKβ and IKKα are core molecules in the canonical and non-canonical NF-κB pathways, respectively .
    6-Chloro-7-deazaguanine
  • HY-128679

    IKK Cancer
    TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC50 values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to PD-1 and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity .
    TBK1/IKKε-IN-5
  • HY-13802
    SC-514
    5+ Cited Publications

    GK 01140

    IKK Cancer
    SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
    SC-514
  • HY-169053

    IKK NF-κB Cancer
    SU1261 is an IKK inhibitor with Ki values of 10 nM and 680 nM for IKKα and IKKβ, respectively. SU1261 can inhibit non-canonical NF-κB signaling in U2OS osteosarcoma cells .
    SU1261
  • HY-124652

    IKK Cancer
    TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective TBK1 and IKKε inhibitor with IC50 values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR .
    TBK1/IKKε-IN-4
  • HY-U00457

    IKK Cancer
    TBK1/IKKε-IN-1 is a dual TBK1 and IKKε inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC50s of <100 nM.
    TBK1/IKKε-IN-1
  • HY-135366

    IKK Inflammation/Immunology
    HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .
    HPN-01
  • HY-13802R

    IKK Cancer
    SC-514 (Standard) is the analytical standard of SC-514. This product is intended for research and analytical applications. SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
    SC-514 (Standard)
  • HY-14682
    GSK319347A
    1 Publications Verification

    IKK Inflammation/Immunology
    GSK319347A is a dual inhibitor of TBK1 and IKKε with IC50s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC50 of 790 nM.
    GSK319347A
  • HY-10074
    TPCA-1
    35+ Cited Publications

    IKK STAT Apoptosis Inflammation/Immunology Cancer
    TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding, and transactivation.
    TPCA-1
  • HY-107591A

    IKK Inflammation/Immunology
    (Rac)-PF-184 hydrate is a potent inhibitory factor-κB kinase 2 (IKK-2) inhibitor with an IC50 of 37 nM. (Rac)-PF-184 hydrate has anti-inflammatory effects .
    (Rac)-PF-184 hydrate
  • HY-107591

    IKK Inflammation/Immunology
    (Rac)-PF-184 is a potent inhibitory factor-κB kinase 2 (IKK-2) inhibitor with an IC50 of 37 nM. (Rac)-PF-184 has anti-inflammatory effects .
    (Rac)-PF-184
  • HY-B0713
    Amlexanox
    20+ Cited Publications

    AA673; Amoxanox; CHX3673

    IKK Metabolic Disease
    Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and TBK1, and inhibits the IKKε and TBK1 activity determined by MBP phosphorylation with an IC50 of approximately 1-2 μM.
    Amlexanox
  • HY-114454
    INH14
    5 Publications Verification

    IKK Inflammation/Immunology Cancer
    INH14 is a cell permeable inhibitor of IKKα/IKKβ, with IC50s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent TLR inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity .
    INH14
  • HY-19362
    AZD3264
    2 Publications Verification

    IKK Inflammation/Immunology
    AZD3264 is a selective IkB-kinase IKK2 inhibitor.
    AZD3264
  • HY-50948
    Bay 65-1942 hydrochloride
    4 Publications Verification

    IKK Inflammation/Immunology
    Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.
    Bay 65-1942 hydrochloride
  • HY-18008
    PS-1145
    4 Publications Verification

    IKK Apoptosis Cancer
    PS-1145 is an IκB kinase (IKK) inhibitor with an IC50 of 88 nM.
    PS-1145
  • HY-14180
    PHA 408
    1 Publications Verification

    IKK Inflammation/Immunology
    PHA 408 (PHA-408) is a potent, selective and orally active IκB kinase-2 (IKK-2) inhibitor. PHA 408 is a powerful anti-inflammatory agent against lipopolysaccharide (LPS)- and cigarette smoke (CS)-mediated lung inflammation .
    PHA 408
  • HY-19383
    Ertiprotafib
    2 Publications Verification

    PTP 112

    Phosphatase IKK PPAR Metabolic Disease
    Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
    Ertiprotafib
  • HY-133117
    BAY-985
    2 Publications Verification

    IKK Cancer
    BAY-985, a chemical probe, is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy .
    BAY-985
  • HY-50949

    IKK Inflammation/Immunology
    Bay 65-1942 free base is an ATP-competitive and selective IKKβ inhibitor.
    Bay 65-1942 free base
  • HY-107591B

    IKK Inflammation/Immunology
    PF-184 is a potent and selective IKK-2 inhibitor (IC50: 37 nM) over rhIKK-1, IKKi, and more than 30 tyrosine and serine/threonine kinases. PF-184 can be used in the research of inflammation, such as asthma and chronic obstructive pulmonary disease .
    PF-184
  • HY-B0713R

    AA673 (Standard); Amoxanox (Standard); CHX3673 (Standard)

    Reference Standards IKK Metabolic Disease
    Amlexanox (Standard) is the analytical standard of Amlexanox. This product is intended for research and analytical applications. Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and TBK1, and inhibits the IKKε and TBK1 activity determined by MBP phosphorylation with an IC50 of approximately 1-2 μM.
    Amlexanox (Standard)
  • HY-B0788A
    LY2409881 trihydrochloride
    3 Publications Verification

    IKK Apoptosis Cancer
    LY2409881 trihydrochloride is a selective IκB kinase β (IKK2) inhibitor with an IC50 of 30 nM.
    LY2409881 trihydrochloride
  • HY-B0788

    IKK Cancer
    LY2409881 is a selective IκB kinase β (IKK2) inhibitor with an IC50 of 30 nM.
    LY2409881
  • HY-N10768

    IKK NF-κB Inflammation/Immunology
    1-Dehydro-[10]-gingerdione directly inhibits IKKβ activity by targeting the activation loop of IKKβ, thus disrupting IKKβ-catalysed IκBα phosphorylation in macrophages stimulated with agonists. 1-Dehydro-[10]-gingerdione inhibits LPS (HY-D1056)-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione has the potential for NF-κB-associated inflammation and autoimmune disorders research .
    1-Dehydro-[10]-gingerdione
  • HY-P10966

    IKK NF-κB Inflammation/Immunology
    Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis .
    Tat-IKIP (46-60)
  • HY-13019
    BI605906
    5+ Cited Publications

    IKK Others
    BI605906, a chemical probe, is a novel IKKβ inhibitor with an IC50 value of 380 nM when assayed at 0.1 mM ATP.
    BI605906
  • HY-18710

    IKK JAK Inflammation/Immunology
    BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively.
    BMS-066

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: